The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease
Open accessAbstract
BACKGROUND: Anacetrapib is a cholesteryl ester transfer protein inhibitor that raises high-density lipoprotein (HDL) cholesterol and reduces low-density lipoprotein (LDL) cholesterol. METHODS: We conducted a randomized, double-blind, placebo-controlled trial to assess the efficacy and safety profile of anacetrapib in patients with coronary heart disease or at high risk for coronary heart disease. Eligible patients who were taking a statin and who had an LDL cholesterol level that was consistent with that recommended in guidelines were assigned to receive 100 mg of anacetrapib or placebo daily for 18 months. The primary end points were the percent change from baseline in LDL cholesterol at 24 weeks (HDL cholesterol level was a secondary end point) and the safety and side-effect profile of anacetrapib through 76 weeks. Cardiovascular events and deaths were prospectively adjudicated. RESULTS: A total of 1623 patients underwent randomization. By 24 weeks, the LDL cholesterol level had been reduced from 81 mg per deciliter (2.1 mmol per liter) to 45 mg per deciliter (1.2 mmol per liter) in the anacetrapib group, as compared with a reduction from 82 mg per deciliter (2.1 mmol per liter) to 77 mg per deciliter (2.0 mmol per liter) in the placebo group (P<0.001)--a 39.8% reduction with anacetrapib beyond that seen with placebo. In addition, the HDL cholesterol level increased from 41 mg per deciliter (1.0 mmol per liter) to 101 mg per deciliter (2.6 mmol per liter) in the anacetrapib group, as compared with an increase from 40 mg per deciliter (1.0 mmol per liter) to 46 mg per deciliter (1.2 mmol per liter) in the placebo group (P<0.001)--a 138.1% increase with anacetrapib beyond that seen with placebo. Through 76 weeks, no changes were noted in blood pressure or electrolyte or aldosterone levels with anacetrapib as compared with placebo. Prespecified adjudicated cardiovascular events occurred in 16 patients treated with anacetrapib (2.0%) and 21 patients receiving placebo (2.6%) (P = 0.40). The prespecified Bayesian analysis indicated that this event distribution provided a predictive probability (confidence) of 94% that anacetrapib would not be associated with a 25% increase in cardiovascular events, as seen with torcetrapib. CONCLUSIONS: Treatment with anacetrapib had robust effects on LDL and HDL cholesterol, had an acceptable side-effect profile, and, within the limits of the power of this study, did not result in the adverse cardiovascular effects observed with torcetrapib. (Funded by Merck Research Laboratories; ClinicalTrials.gov number, NCT00685776.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in humans, elevated cholesterol levels are a major risk factor for the development of cardiovascular disease (Cannon et al., 2010).”
From Population genomics reveal recent speciation and rapid evolutionary adaptation in polar bears (2014) · cites this paper as Cannon et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Self-citationIntensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citationEffects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationPedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548
Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774
Thompson, A. (2008) · JAMA · doi:10.1001/jama.299.23.2777 · Cited by 498
Forrest, M. J., Bloomfield, D. M., Briscoe, R. J., Brown, P. N., Cumiskey, A., Ehrhart, J., Hershey, J. C., Keller, W. J., Ma, X., McPherson, H. E., et al. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.229 · Cited by 293
Krishna, R., Anderson, M. S., Bergman, A. J., Jin, B., Fallon, M. S., Côté, J., Rosko, K., Chavez-Eng, C. M., Lutz, R., Bloomfield, D. M., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61813-3 · Cited by 275
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 752
Critical review of non-statin treatments for dyslipoproteinemia
Pang, J., Chan, D. C., & Watts, G. F. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.888312 · Cited by 6
Drugs Targeting High-Density Lipoprotein Cholesterol for Coronary Artery Disease Management
Katz, P. M., & Leiter, L. A. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.03.017 · Cited by 6
Jamalan, M., Zeinali, M., & Ghaffari, M. A. (2015) · Medicinal Chemistry Research · doi:10.1007/s00044-015-1471-0 · Cited by 6
Quintão, E. C. R. (2016) · European Journal of Clinical Investigation · doi:10.1111/eci.12626 · Cited by 6
The Year in Non–ST-Segment Elevation Acute Coronary Syndrome
Giugliano, R. P., & Braunwald, E. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.08.042 · Cited by 6
Pharmacogenomics in the Development and Characterization of Atheroprotective Drugs
Valanti, E., Tsompanidis, A., & Sanoudou, D. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0956-8_11 · Cited by 6
Is Anacetrapib Better Than Its CETP Inhibitor Counterparts?
Grabie, M., Tai, C.-H., & Frishman, W. H. (2018) · Cardiology in Review · doi:10.1097/crd.0000000000000245 · Cited by 6
Halcox, J. (2013) · Clinical Lipidology · doi:10.2217/clp.13.16 · Cited by 6
Combination lipid therapy in type 2 diabetes mellitus
Vergès, B. L. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.558503 · Cited by 6
Xie, H., Li, Y., Bai, C., Wang, R., Liu, C., Hao, C., Lin, B., Cheng, M., & Zhao, D. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.03.002 · Cited by 6
HyperLp(a)lipoproteinaemia: unmet need of diagnosis and treatment?
Stefanutti, C., & Morozzi, C. (2016) · Europe PMC (PubMed Central) · doi:10.2450/2016.0027-16 · Cited by 6
Ye, Z., Lü, H., Long, M., & Li, L. (2018) · Disease Markers · doi:10.1155/2018/9731374 · Cited by 6
The Evolution or Revolution of Statin Therapy in Primary Prevention: Where Do We Go From Here?
Rehfield, P., Kopes-Kerr, C. P., & Clearfield, M. B. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0298-0 · Cited by 6
Lepodisiran: Effects on Lipoprotein(a) and Cardiovascular Outcomes in Adults with Elevated Lp(a)
Kattamuri, L. P. V., Sharma, K., & Mukherjee, D. (2025) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x390148250908045359 · Cited by 5
Lian, P., Zhu, W.-Q., Zhao, W.-X., Huang, P., Ran, J., Tang, Y., Huang, X., & Li, R. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.119982 · Cited by 5
Elis, A., Pereg, D., Froom, P., Lishner, M., Segev, D., & Hermoni, D. (2011) · Clinical Cardiology · doi:10.1002/clc.20944 · Cited by 5
Emerging drugs for hyperlipidaemia: an update
Florentin, M., Kostapanos, M. S., Kei, A. A., & Elisaf, M. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.976553 · Cited by 5
Reduction in PCSK9 levels induced by anacetrapib: an off-target effect?
Barter, P. J., Tabet, F., & Rye, K. (2015) · Journal of Lipid Research · doi:10.1194/jlr.c063768 · Cited by 5
Self-citationTeramoto, T., Kiyosue, A., Iimura, T., Takita, Y., Riesmeyer, J. S., & Murakami, M. (2017) · Circulation Journal · doi:10.1253/circj.cj-16-1325 · Cited by 5
Wang, Y., Yang, W., Finlay, H. J., Harikrishnan, L. S., Jiang, J., Kamau, M. G., Kirk, K. V., Nirschl, D. S., Taylor, D. S., Chen, A. Y. A., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.12.088 · Cited by 5
Nissen, S. E. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.208 · Cited by 5
Wilkinson, M. J., & Davidson, M. H. (2013) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-013-0272-3 · Cited by 5
Self-citationHDL–Cholesterol: Perfection is the Enemy of Good?
Baliga, R. R. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.01.001 · Cited by 5
The DEFINE study: a bright future for CETP inhibitors?
Katsiki, N., Athyros, V. G., & Mikhailidis, D. P. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.550571 · Cited by 5
Krishna, R., Gheyas, F., Liu, Y., Côté, J., Laterza, O., Ruckle, J., Wagner, J. A., & Denker, A. E. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1004 · Cited by 5
Lipid-modifying and antiatherosclerotic drugs
Gotto, A. M., & Opie, L. H. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-3322-4.00019-3 · Cited by 5
Self-citationKalgutkar, A. S. S., Frederick, K. S., Hatch, H. L., Ambler, C. M., Perry, D. A., Garigipati, R. S., Chang, G., Lefker, B. A., Clark, R. W., Morehouse, L. A., et al. (2013) · Xenobiotica · doi:10.3109/00498254.2013.874611 · Cited by 5
Айтбаев, К. А., Murkamilov, I. T., & Fomin, V. V. (2019) · Kardiologiia · doi:10.18087/cardio.2019.2.10231 · Cited by 5
Levinson, S. S. (2017) · Clinica Chimica Acta · doi:10.1016/j.cca.2017.11.001 · Cited by 5
Lipoprotein(a), Ethnicity, and Cardiovascular Risk
Ridker, P. M. (2011) · Circulation · doi:10.1161/circulationaha.111.077354 · Cited by 5
New perspectives in cardiovascular risk reduction: focus on HDL
Paolillo, S., Ratta, G. L. D., Vitagliano, A., Cirillo, A., Lardino, E., Formisano, T., Fabiani, I., Pellegrino, A. M., Riello, P., & Filardi, P. P. (2015) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2013.88 · Cited by 4
Khalil, I., Islam, M. R., Promi, S. A., Joy, A. D., Sayed, M. A., Acharjee, D., Al‐Shammari, A. S., Abrar, S., Jamil, T. B., Taseen, M., et al. (2025) · Clinical Cardiology · doi:10.1002/clc.70204 · Cited by 4
Lipoprotein(a) Lowering with Pelacarsen (TQJ230)
Sharma, K., Kattamuri, L. P. V., & Mukherjee, D. (2025) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x399029250923100015 · Cited by 4
CETP Inhibitors: Back With a New Target
Nicholls, S. J., Ray, K. K., Nelson, A. J., & Kastelein, J. J. P. (2026) · Circulation Research · doi:10.1161/circresaha.125.327271 · Cited by 4
Novedades en cardiología clínica: nuevos enfoques de viejos retos
Borràs, X., Murga, N., Ripoll, T., & Gómez‐Doblas, J. J. (2012) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.10.033 · Cited by 4
Disfunción tiroidea y lipídica asociada a bexaroteno en el linfoma cutáneo de células T
Suárez, S. R., Andreu, E. P., Grijalvo, O. M., & Morillo, J. S. G. (2015) · Medicina Clínica · doi:10.1016/j.medcli.2015.07.017 · Cited by 4
Wijeysundera, H. C., Koh, M., Alter, D. A., Austin, P. C., Jackevicius, C. A., Tu, J. V., & Ko, D. T. (2017) · Open Heart · doi:10.1136/openhrt-2017-000731 · Cited by 4
Semenkovich, C. F. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00213-x · Cited by 7
Impact of Increased Gastric pH on the Pharmacokinetics of Evacetrapib in Healthy Subjects
Small, D. S., Royalty, J. E., Cannady, E. A., Hale, C., Wang, M., Downs, D., & Suico, J. G. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1778 · Cited by 4
Libby, P. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2930-6.00008-2 · Cited by 4
Clinical Strategies for Managing Dyslipidemias
Bronas, U. G., & Salisbury, D. L. (2013) · American Journal of Lifestyle Medicine · doi:10.1177/1559827613507534 · Cited by 5
Trial puts niacin—and cholesterol dogma—in the line of fire
Dolgin, E. (2011) · Nature Medicine · doi:10.1038/nm0711-756 · Cited by 4
Sliskovic, D. R. (2013) · Drug Discovery · doi:10.1002/9781118354483.ch5 · Cited by 4
Emerging Therapies for Residual Risk
Mehra, S., Movahed, H., & Movahed, A. (2012) · Reviews in Cardiovascular Medicine · doi:10.3909/ricm0583 · Cited by 3
Phase III Trial of Dalcetrapib
Sweetlove, M. (2012) · Pharmaceutical Medicine · doi:10.1007/bf03262483 · Cited by 3
Hochholzer, W., & Giugliano, R. P. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0290-8 · Cited by 3
Arteaga, A., & Rigotti, A. (2011) · Revista médica de Chile · doi:10.4067/s0034-98872011000600016 · Cited by 3
Robinson, L. B., & Frishman, W. H. (2014) · Cardiology in Review · doi:10.1097/crd.0000000000000023 · Cited by 3
Brown, A. L., & Brown, J. M. (2017) · Journal of Lipid Research · doi:10.1194/jlr.c077131 · Cited by 3
Thompson, P. L., Thompson, A., & Judkins, C. (2014) · The Medical Journal of Australia · doi:10.5694/mja14.01155 · Cited by 3
Marinho, A. T., Batuca, J. R., Miranda, J. P., Caixas, U., Dias, C. G., Branco, T. L., Soto, K., Pinheiro, P. F., Bourbon, M., Marques, M. M., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105446 · Cited by 3
Sinha, T., Guntha, M., Mayow, A. H., Zin, A. K., Chaudhari, S. S., Khan, M. W., Kholoki, S., & Khan, A. A. (2024) · Cureus · doi:10.7759/cureus.61069 · Cited by 3
Doggrell, S. A. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.659817 · Cited by 3
King, A. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.196 · Cited by 3
Lipoprotein(a): epidemiology, atherogenic activity and impact on cardiovascular risk
Phan, B. A. P., & Toth, P. P. (2013) · Clinical Lipidology · doi:10.2217/clp.13.9 · Cited by 3
Yagyu, H., Nagashima, S., Takahashi, M., Miyamoto, M., Okada, K., Osuga, J.-I., & Ishibashi, S. (2012) · Endocrine Journal · doi:10.1507/endocrj.ej12-0132 · Cited by 3
Corral, P., & Schreier, L. E. (2013) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2013.08.002 · Cited by 3
Treatment Targets in the Management of Dyslipidemias: Which Targets in Whom?
Grundy, S. M. (2012) · Current Cardiology Reports · doi:10.1007/s11886-012-0305-7 · Cited by 3
KONES, R. J. (2013) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944712467828 · Cited by 3
Acute high-density lipoprotein therapies
Duong, M., Bartolo, B. A. D., & Nicholls, S. J. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000235 · Cited by 3
European Society of Cardiology (ESC) Annual Congress Report From Barcelona 2017
Satoh, K., TAKAHASHI, J. C., Matsumoto, Y., Tatebe, S., Aoki, T., Kikuchi, Y., Hao, K., Ohyama, K., Nogi, M., Suda, A., et al. (2017) · Circulation Journal · doi:10.1253/circj.cj-17-1103 · Cited by 3
Emerging Cholesterol Modulators for Atherosclerotic Cardiovascular Disease
Noh, S., Mai, K., Shaver, M., Yong, S., MOSTAGHIMI, M., Oh, G., & Radwan, M. M. (2022) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2021.12.011 · Cited by 3
Koschinsky, M. L., Boffa, M. B., & Marcovina, S. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00010-4 · Cited by 3
Combination Therapy for Dyslipidemia
Davidson, D., Wilkinson, M. J., & Davidson, M. H. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00027-x · Cited by 3
Self-citationGenomics and Pharmacogenomics of Lipid-Lowering Therapies
Docherty, K. F., & Padmanabhan, S. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386882-4.00031-1 · Cited by 3
Novel Cholesteryl Ester Transfer Protein Inhibitors: Promising Therapy for Dyslipidemia?
Devaraj, S., & Jialal, I. (2011) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2011.1500 · Cited by 3
Good news for 'good' cholesterol
Katsnelson, A. (2010) · Nature · doi:10.1038/468354a · Cited by 3
Wiviott, S. D. (2011) · Circulation · doi:10.1161/circulationaha.111.043323 · Cited by 3
Fazio, S., & Linton, M. F. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.091 · Cited by 3
Hu, H., Mao, J., Zhao, Y., Zhang, Y., Zhuang, C., He, J., & Yang, X. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100067 · Cited by 2
Jang, A. Y., Lee, J. H., Lee, S., Choe, H. J., Park, S. M., Jeong, I., Kim, B. J., & on behalf of the Lipoprotein(a) Task Force of the Korea Society of Lipid and Atherosclerosis (2025) · Korean Circulation Journal · doi:10.4070/kcj.2025.0388 · Cited by 2
Jang, A. Y., Lee, J. H., Lee, S.-G., Choe, H. J., Park, S. M., Jeong, I., Kim, B. J., & on behalf of the Lipoprotein(a) Task Force of the Korea Society of Lipid and Atherosclerosis (2026) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2026.15.1.2 · Cited by 2
Drugs in development for management of lipoprotein disorders
Brown, W. V., Bays, H. E., Davidson, M. H., & Goldberg, A. C. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.01.004 · Cited by 2
Self-citationImproving the odds: ezetimibe and cardiovascular disease
Viljoen, A., & Wierzbicki, A. S. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12613 · Cited by 2
Low-Density Lipoprotein Lowering in 2013 by Nonstatin Agents
Kohli, P., & Giugliano, R. P. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413480270 · Cited by 2
Doggrell, S. A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1448061 · Cited by 2
Lipoproteins and Cardiovascular Disease Risk
Dhingra, R., & Vasan, R. S. (2015) · Contemporary Endocrinology · doi:10.1007/978-1-60761-424-1_4 · Cited by 2
Clinical Outcomes in Trials Evaluating Lipid-Lowering Drugs
Butters, J., Brown, A. D. H., Griffith, L., Kim, H., & Nicholls, S. J. (2017) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-017-0231-6 · Cited by 2
Reverse Cholesterol Transport in HDL Metabolism
Guérin, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-812513-7.00005-7 · Cited by 2
Study of effect modifiers of genetically predicted CETP reduction
Legault, M., Barhdadi, A., Gamache, I., Lemaçon, A., Perreault, L. L., Grenier, J., Sylvestre, M., Hussin, J., Rhainds, D., Tardif, J., et al. (2023) · Genetic Epidemiology · doi:10.1002/gepi.22514 · Cited by 2
Zhang, R., Xie, Q., & Xiao, P. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1260679 · Cited by 2
Besqueut‐Rougerie, C., Chavanelle, V., Michaux, A., Otero, Y. F., Sirvent, P., King, J. A., & Ennequin, G. (2024) · Physiological Reports · doi:10.14814/phy2.15993 · Cited by 2
Chen, L., Ma, J., Xu, W., Shen, F., Yang, Z., Sonne, C., Dietz, R., Li, L., Jie, X., Li, L., et al. (2024) · Evolutionary Applications · doi:10.1111/eva.13731 · Cited by 2
Hypertension, Obesity, and Metabolic Syndrome
Nilsson, P. M. (2012) · Springer eBooks · doi:10.1007/978-88-470-2601-8_11 · Cited by 2
Clinical significance and treatment options of increased lipoprotein(a)
Zsíros, N., Paragh, G., & Harangi, M. (2014) · Orvosi Hetilap · doi:10.1556/oh.2014.29877 · Cited by 2
Mankovsky, B. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0200 · Cited by 2
CETP inhibition in perspective
Stock, J. K. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.10.008 · Cited by 2
The inhibition of cholesteryl ester transfer protein: a long and winding road
Rye, K., & Barter, P. J. (2012) · Journal of Lipid Research · doi:10.1194/jlr.e027334 · Cited by 2
Self-citationKim, J., & Lee, S. Y. (2013) · The Korean Journal of Obesity · doi:10.7570/kjo.2013.22.2.67 · Cited by 2
What do we know about lipoprotein(a)?
Cybulska, B., & Kłosiewicz−Latoszek, L. (2015) · Kardiologia Polska · doi:10.5603/kp.a2014.0244 · Cited by 2
Thyroid and lipidic dysfunction associated with bexarotene in cutaneous T-cell lymphoma
Suárez, S. R., Andreu, E. P., Grijalvo, O. M., & Morillo, J. S. G. (2016) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2015.07.004 · Cited by 2
Cholesteryl Ester Transfer Protein Inhibitors
Inazu, A. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-407867-3.00008-1 · Cited by 2
Advances in the management of dyslipidemia
Kampangkaew, J., Pickett, S., & Nambi, V. (2017) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000415 · Cited by 2
Genetic Disorders of HDL Metabolism
Lilley, J. S., Linton, M. F., & Fazio, S. (2015) · Contemporary Endocrinology · doi:10.1007/978-1-60761-424-1_12 · Cited by 2
Lipid management in Type 2 diabetes: the case for combination therapy?
Saely, C. H., Drexel, V., Vonbank, A., & Drexel, H. (2011) · Therapy · doi:10.2217/thy.11.5 · Cited by 2
Ali, A., & Duffy, J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12463-1 · Cited by 2
Wierzbicki, A. S. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000453 · Cited by 2
Bayesian Adaptive Trials for Rare Cardiovascular Conditions
Shohoudi, A., Stephens, D. A., & Khairy, P. (2018) · Future Cardiology · doi:10.2217/fca-2017-0040 · Cited by 2
Kruithof, A. C., Kumar, R., Stevens, J., de Kam, M. L., Gautam, A., Alikunju, S., Padhi, B. K., Kulkarni, S., Raghuvanshi, R. S., Gandhi, R., et al. (2019) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.707 · Cited by 2
Torcetrapib and Dalcetrapib Safety: Relevance of Preclinical In Vitro and In Vivo Models
Niesor, E. J., Greiter‐Wilke, A., & Müller, L. (2015) · Methods and principles in medicinal chemistry · doi:10.1002/9783527673643.ch19 · Cited by 2
Metadata
- Authors
- Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., Stepanavage, M., Liu, S. X., Gibbons, P., Ashraf, T. B., Zafarino, J., Mitchel, Y., & Barter, P.
- Affiliations
- Brigham and Women's Hospital (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Radiant Research (United States) (US)
- University of Utah (US)
- The Heart Research Institute (AU)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-12-16
- Volume
- 363
- Issue
- 25
- Pages
- 2406-2415
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2090464684
- Cited by
- 749
- References
- 17
- Citations by year
- 2026: 13 · 2025: 7 · 2024: 13 · 2023: 13 · 2022: 16 · 2021: 18 · 2020: 18 · 2019: 21 · 2018: 26 · 2017: 54 · 2016: 68 · 2015: 83 · 2014: 83 · 2013: 92 · 2012: 116
- FWCI
- 107.18
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- anacetrapib, cholesteryl ester transfer protein inhibitors, coronary artery disease, LDL cholesterol lowering, HDL cholesterol, statin combination therapy, cardiovascular safety, cardiovascular events, drug safety, high-risk patients, lipid-lowering therapy, blood pressure, electrolytes, aldosterone, Bayesian hierarchical model, cardiovascular hospitalization
- MeSH terms
- Adult, Aged, Anticholesteremic Agents, Bayes Theorem, Combined Modality Therapy, Coronary Disease, Double-Blind Method, Female, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Risk Factors, Oxazolidinones, Cholesterol Ester Transfer Proteins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
